RPS3 and hepatocellular carcinoma: The inhibition of RPS3/SIRT1 pathway by 5-formylfuran-2-yl methyl 4-hydroxy-2-methylenebutanoate (FMHM) represses HCC progression suggesting that RPS3/SIRT1 could serve as a potential therapeutic target in liver cancer [86].